Canbridge Life Science's shares surged 34% after announcing a HKD 100 million (USD 12.8 million) strategic investment from Chinese compatriot Baheal Medical, which will acquire a 14.99% stake at HKD 1.34 per share. The deal includes a commercialisation agreement granting Baheal rights to promote select Canbridge rare disease products in mainland China, Hong Kong and Macau. The partnership aims to enhance Canbridge's commercial capabilities and accelerate market penetration of its approved therapies.

The collaboration leverages Baheal's established commercialisation platform to expand access to Canbridge's rare disease portfolio. Both companies saw share price gains following the announcement, with Canbridge's market capitalisation reaching HKD 952 million and Baheal's rising 3% to RMB 14.3 billion. The deal represents a significant step in China's rare disease market development, combining Canbridge's pipeline with Baheal's distribution expertise.

PharmCube's NextBiopharm® database shows that this is Canbridge's first deal as transferor, as opposed to its usual scheme of in-licensing external assets. Click here to request a free trial for NextBiopharm®.